Have you checked out our newsletter?
Stay ahead with expert insights, strategic tips, and industry trends—all designed to boost your brand's med comm initiatives.
"*" indicates required fields
Get fresh insights and candid perspectives on timely issues impacting the pharmaceutical industry from our blog.
The Latest News
Will Your Launch Strategy Succeed or Fail?
The Challenge: A Faster, More Complex Launch Environment In today’s pharmaceutical market, strong science is the foundation, but it doesn’t always guarantee a successful launch. Many of us have experienced a disappointing launch when everything we anticipated pointed to success. Today, launches are more complex than they were a decade
Industry Happenings -September 2026
FDA policy, shifting R&D priorities, and heightened oversight of overseas trials are shaping the future of drug development. Don’t miss the latest in BioPharma! Source: PharmaVoice The upcoming reauthorization of the Prescription Drug User Fee Act (PDUFA) could create an opening for Congress to streamline U.S. clinical trials as competition
132 Speakers. Three Leadership Changes. No Compromise on Speaker Readiness: A Case Study
Business throws a lot of curveballs. Deadlines tighten. Priorities shift. And sometimes, leadership changes overnight. When you’re navigating that kind of disruption, having a partner who already knows your business can make all the difference. There’s no time to start from scratch or get up to speed on what needs
Industry Insights – June 2026
From evolving China deal dynamics and prolonged job searches to the growing push for AI-driven drug repurposing, explore how shifts in BioPharma are redefining innovation, hiring, and strategy across the sector. Don’t miss the latest: Source: PharmaVoice The FDA is ramping up efforts to identify new uses for existing drugs,
Industry Insights – May 2026
Biosimilars are gaining U.S. momentum even as patent thickets keep triggering legal fights, small biotechs are feeling the pressure of the FDA’s faster-moving approval environment, and the agency is testing real-time clinical trial review with big-name drugmakers already on board. It’s a fast-changing drug-development landscape worth watching. Don’t miss the
Virtual Speaker Programs for Busy Providers
The Biggest Challenge Is Not Lack of Information In the current healthcare environment, new drugs are being approved by the FDA daily. Imagine a healthcare provider who sees a patient recently diagnosed with obesity and is looking to start a weight-loss program. The physician has a busy practice. She often finds it time-consuming
BioPharma in the News – April 2026
The FDA is escalating its ongoing push for transparency and tougher enforcement, including publicizing complete response letters, seeking new authority over DTC drug advertising, and tightening expectations around external controls in rare disease trials. Don’t miss the latest in the industry. Source: PharmaVoice The FDA’s push for “radical transparency” is
When the Universe Has Other Plans: How to Save a Speaker Program in Crisis
It’s the perfect storm: TSA staffing shortages, extreme weather, constant flight delays, and airlines cutting hundreds of flights daily1. There is an in-person speaker program tonight. Your scheduled speaker wakes up to a ping on his phone at 4:30 am and finds the dreaded message: “We have been notified by
What’s Trending in BioPharma – March 2026
Europe risks falling behind in the global BioPharma race, the FDA is working to increase accessibility to personalized treatments in rare diseases, and regulators are cracking down on unapproved compounded GLP-1 weight loss drugs. Together, these three stories show the shifting landscape of innovation, regulation, and competition shaping the BioPharma